[{"address1": "11711 North Meridian Street", "address2": "Suite 300", "city": "Carmel", "state": "IN", "zip": "46032", "country": "United States", "phone": "317 659 0200", "website": "https://mbxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.", "fullTimeEmployees": 43, "companyOfficers": [{"maxAge": 1, "name": "Mr. Peter Kent Hawryluk MBA", "age": 56, "title": "CEO, President & Director", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 788300, "exercisedValue": 0, "unexercisedValue": 12366896}, {"maxAge": 1, "name": "Mr. Richard B. Bartram CPA", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 642001, "exercisedValue": 0, "unexercisedValue": 3084960}, {"maxAge": 1, "name": "Dr. Salomon  Azoulay M.D.", "age": 68, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 520512, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steven L. Hoerter", "age": 54, "title": "Executive Chairperson", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Gambino", "title": "Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Graham", "age": 58, "title": "Chief Human Resources Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Dorato DABT, Ph.D.", "title": "Sr. Vice President of Discovery & Non-Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chatan  Charan Ph.D.", "title": "Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Hope", "title": "Senior Vice President of Regulatory & Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Moraitis M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 38.0, "open": 38.07, "dayLow": 37.69, "dayHigh": 40.09, "regularMarketPreviousClose": 38.0, "regularMarketOpen": 38.07, "regularMarketDayLow": 37.69, "regularMarketDayHigh": 40.09, "payoutRatio": 0.0, "trailingPE": 4.9661016, "forwardPE": -12.428947, "volume": 545398, "regularMarketVolume": 545398, "averageVolume": 761559, "averageVolume10days": 726940, "averageDailyVolume10Day": 726940, "bid": 37.84, "ask": 38.4, "bidSize": 1, "askSize": 1, "marketCap": 1710328704, "fiftyTwoWeekLow": 4.807, "fiftyTwoWeekHigh": 44.89, "allTimeHigh": 44.89, "allTimeLow": 4.807, "fiftyDayAverage": 34.2722, "twoHundredDayAverage": 19.963924, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1319278720, "profitMargins": 0.0, "floatShares": 27444287, "sharesOutstanding": 44902302, "sharesShort": 1965975, "sharesShortPriorMonth": 3843943, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0438, "heldPercentInsiders": 0.028380001, "heldPercentInstitutions": 1.1083599, "shortRatio": 2.84, "shortPercentOfFloat": 0.07, "impliedSharesOutstanding": 44902302, "bookValue": 8.667, "priceToBook": 4.394831, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -80495000, "trailingEps": 7.67, "forwardEps": -3.06462, "enterpriseToEbitda": -14.558, "52WeekChange": 2.4944954, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 38.09, "targetHighPrice": 88.0, "targetLowPrice": 18.0, "targetMeanPrice": 61.1, "targetMedianPrice": 63.0, "recommendationKey": "none", "numberOfAnalystOpinions": 10, "totalCash": 391672992, "totalCashPerShare": 8.723, "ebitda": -90624000, "totalDebt": 623000, "quickRatio": 32.6, "currentRatio": 32.955, "debtToEquity": 0.161, "returnOnAssets": -0.16643, "returnOnEquity": -0.24433, "freeCashflow": -50834752, "operatingCashflow": -77685000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MBX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "MBX Biosciences, Inc.", "longName": "MBX Biosciences, Inc.", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1771017004, "regularMarketTime": 1771016401, "exchange": "NMS", "messageBoardId": "finmb_613097171", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.236842, "regularMarketPrice": 38.09, "fiftyDayAverageChange": 3.8177986, "fiftyDayAverageChangePercent": 0.111396365, "twoHundredDayAverageChange": 18.126076, "twoHundredDayAverageChangePercent": 0.9079415, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-09-13", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1726234200000, "postMarketChangePercent": 0.0, "postMarketPrice": 38.09, "postMarketChange": 0.0, "regularMarketChange": 0.0900002, "regularMarketDayRange": "37.69 - 40.09", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 761559, "fiftyTwoWeekLowChange": 33.283, "fiftyTwoWeekLowChangePercent": 6.923861, "fiftyTwoWeekRange": "4.807 - 44.89", "fiftyTwoWeekHighChange": -6.799999, "fiftyTwoWeekHighChangePercent": -0.15148139, "fiftyTwoWeekChangePercent": 249.44954, "earningsTimestampStart": 1762435800, "earningsTimestampEnd": 1762435800, "earningsCallTimestampStart": 1754564400, "earningsCallTimestampEnd": 1754564400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 7.67, "epsForward": -3.06462, "epsCurrentYear": -2.51511, "priceEpsCurrentYear": -15.144466, "displayName": "MBX Biosciences", "trailingPegRatio": null, "__fetch_time": "2026-02-14"}]